<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d213" origId="Bezafibrate"><sentence id="DrugDDI.d213.s0" origId="s0" text="When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type."><entity id="DrugDDI.d213.s0.e0" origId="s0.p1" charOffset="5-12" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s0.e1" origId="s0.p3" charOffset="16-23" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s0.e2" origId="s0.p7" charOffset="65-74" type="drug" text="medicines"/><entity id="DrugDDI.d213.s0.e3" origId="s0.p15" charOffset="146-153" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s0.e4" origId="s0.p17" charOffset="158-165" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s0.e5" origId="s0.p21" charOffset="199-213" type="drug" text="anticoagulants"/><entity id="DrugDDI.d213.s0.e6" origId="s0.p22" charOffset="221-229" type="drug" text="coumarin"/><pair id="DrugDDI.d213.s0.p0" e1="DrugDDI.d213.s0.e0" e2="DrugDDI.d213.s0.e1" interaction="false"/><pair id="DrugDDI.d213.s0.p1" e1="DrugDDI.d213.s0.e0" e2="DrugDDI.d213.s0.e2" interaction="false"/><pair id="DrugDDI.d213.s0.p2" e1="DrugDDI.d213.s0.e0" e2="DrugDDI.d213.s0.e3" interaction="false"/><pair id="DrugDDI.d213.s0.p3" e1="DrugDDI.d213.s0.e0" e2="DrugDDI.d213.s0.e4" interaction="false"/><pair id="DrugDDI.d213.s0.p4" e1="DrugDDI.d213.s0.e0" e2="DrugDDI.d213.s0.e5" interaction="false"/><pair id="DrugDDI.d213.s0.p5" e1="DrugDDI.d213.s0.e0" e2="DrugDDI.d213.s0.e6" interaction="false"/><pair id="DrugDDI.d213.s0.p6" e1="DrugDDI.d213.s0.e1" e2="DrugDDI.d213.s0.e2" interaction="false"/><pair id="DrugDDI.d213.s0.p7" e1="DrugDDI.d213.s0.e1" e2="DrugDDI.d213.s0.e3" interaction="false"/><pair id="DrugDDI.d213.s0.p8" e1="DrugDDI.d213.s0.e1" e2="DrugDDI.d213.s0.e4" interaction="false"/><pair id="DrugDDI.d213.s0.p9" e1="DrugDDI.d213.s0.e1" e2="DrugDDI.d213.s0.e5" interaction="false"/><pair id="DrugDDI.d213.s0.p10" e1="DrugDDI.d213.s0.e1" e2="DrugDDI.d213.s0.e6" interaction="false"/><pair id="DrugDDI.d213.s0.p11" e1="DrugDDI.d213.s0.e2" e2="DrugDDI.d213.s0.e3" interaction="false"/><pair id="DrugDDI.d213.s0.p12" e1="DrugDDI.d213.s0.e2" e2="DrugDDI.d213.s0.e4" interaction="false"/><pair id="DrugDDI.d213.s0.p13" e1="DrugDDI.d213.s0.e2" e2="DrugDDI.d213.s0.e5" interaction="false"/><pair id="DrugDDI.d213.s0.p14" e1="DrugDDI.d213.s0.e2" e2="DrugDDI.d213.s0.e6" interaction="false"/><pair id="DrugDDI.d213.s0.p15" e1="DrugDDI.d213.s0.e3" e2="DrugDDI.d213.s0.e4" interaction="false"/><pair id="DrugDDI.d213.s0.p16" e1="DrugDDI.d213.s0.e3" e2="DrugDDI.d213.s0.e5" interaction="true"/><pair id="DrugDDI.d213.s0.p17" e1="DrugDDI.d213.s0.e3" e2="DrugDDI.d213.s0.e6" interaction="true"/><pair id="DrugDDI.d213.s0.p18" e1="DrugDDI.d213.s0.e4" e2="DrugDDI.d213.s0.e5" interaction="true"/><pair id="DrugDDI.d213.s0.p19" e1="DrugDDI.d213.s0.e4" e2="DrugDDI.d213.s0.e6" interaction="true"/><pair id="DrugDDI.d213.s0.p20" e1="DrugDDI.d213.s0.e5" e2="DrugDDI.d213.s0.e6" interaction="false"/></sentence><sentence id="DrugDDI.d213.s1" origId="s1" text="For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters"><entity id="DrugDDI.d213.s1.e0" origId="s1.p25" charOffset="33-46" type="drug" text="anticoagulant"/><entity id="DrugDDI.d213.s1.e1" origId="s1.p32" charOffset="108-115" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s1.e2" origId="s1.p34" charOffset="119-126" type="drug" text="Bezalip"/><pair id="DrugDDI.d213.s1.p0" e1="DrugDDI.d213.s1.e0" e2="DrugDDI.d213.s1.e1" interaction="true"/><pair id="DrugDDI.d213.s1.p1" e1="DrugDDI.d213.s1.e0" e2="DrugDDI.d213.s1.e2" interaction="true"/><pair id="DrugDDI.d213.s1.p2" e1="DrugDDI.d213.s1.e1" e2="DrugDDI.d213.s1.e2" interaction="false"/></sentence><sentence id="DrugDDI.d213.s2" origId="s2" text="."/><sentence id="DrugDDI.d213.s3" origId="s3" text="- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard."><entity id="DrugDDI.d213.s3.e0" origId="s3.p40" charOffset="16-31" type="drug" text="sulphonylureas"/><entity id="DrugDDI.d213.s3.e1" origId="s3.p42" charOffset="35-42" type="drug" text="insulin"/><entity id="DrugDDI.d213.s3.e2" origId="s3.p46" charOffset="62-69" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s3.e3" origId="s3.p48" charOffset="73-80" type="drug" text="Bezalip"/><pair id="DrugDDI.d213.s3.p0" e1="DrugDDI.d213.s3.e0" e2="DrugDDI.d213.s3.e1" interaction="false"/><pair id="DrugDDI.d213.s3.p1" e1="DrugDDI.d213.s3.e0" e2="DrugDDI.d213.s3.e2" interaction="true"/><pair id="DrugDDI.d213.s3.p2" e1="DrugDDI.d213.s3.e0" e2="DrugDDI.d213.s3.e3" interaction="true"/><pair id="DrugDDI.d213.s3.p3" e1="DrugDDI.d213.s3.e1" e2="DrugDDI.d213.s3.e2" interaction="true"/><pair id="DrugDDI.d213.s3.p4" e1="DrugDDI.d213.s3.e1" e2="DrugDDI.d213.s3.e3" interaction="true"/><pair id="DrugDDI.d213.s3.p5" e1="DrugDDI.d213.s3.e2" e2="DrugDDI.d213.s3.e3" interaction="false"/></sentence><sentence id="DrugDDI.d213.s4" origId="s4" text="This may be due to an improved glucose utilization with simultaneous reduction in insulin requirement"><entity id="DrugDDI.d213.s4.e0" origId="s4.p52" charOffset="31-38" type="drug" text="glucose"/><entity id="DrugDDI.d213.s4.e1" origId="s4.p54" charOffset="82-89" type="drug" text="insulin"/><pair id="DrugDDI.d213.s4.p0" e1="DrugDDI.d213.s4.e0" e2="DrugDDI.d213.s4.e1" interaction="false"/></sentence><sentence id="DrugDDI.d213.s5" origId="s5" text="."/><sentence id="DrugDDI.d213.s6" origId="s6" text="- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate."><entity id="DrugDDI.d213.s6.e0" origId="s6.p73" charOffset="254-265" type="drug" text="bezafibrate"/></sentence><sentence id="DrugDDI.d213.s7" origId="s7" text="Accordingly, renal function should be closely monitored in these patients and, in the event of relevant significant changes in laboratory parameters, bezafibrate should, if necessary, be discontinued"><entity id="DrugDDI.d213.s7.e0" origId="s7.p86" charOffset="150-161" type="drug" text="bezafibrate"/></sentence><sentence id="DrugDDI.d213.s8" origId="s8" text="."/><sentence id="DrugDDI.d213.s9" origId="s9" text="- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired"><entity id="DrugDDI.d213.s9.e0" origId="s9.p95" charOffset="7-14" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s9.e1" origId="s9.p97" charOffset="18-25" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s9.e2" origId="s9.p101" charOffset="59-81" type="drug" text="anion-exchange resins"/><entity id="DrugDDI.d213.s9.e3" origId="s9.p112" charOffset="174-183" type="drug" text="medicines"/><entity id="DrugDDI.d213.s9.e4" origId="s9.p115" charOffset="209-216" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s9.e5" origId="s9.p117" charOffset="220-227" type="drug" text="Bezalip"/><pair id="DrugDDI.d213.s9.p0" e1="DrugDDI.d213.s9.e0" e2="DrugDDI.d213.s9.e1" interaction="false"/><pair id="DrugDDI.d213.s9.p1" e1="DrugDDI.d213.s9.e0" e2="DrugDDI.d213.s9.e2" interaction="false"/><pair id="DrugDDI.d213.s9.p2" e1="DrugDDI.d213.s9.e0" e2="DrugDDI.d213.s9.e3" interaction="false"/><pair id="DrugDDI.d213.s9.p3" e1="DrugDDI.d213.s9.e0" e2="DrugDDI.d213.s9.e4" interaction="false"/><pair id="DrugDDI.d213.s9.p4" e1="DrugDDI.d213.s9.e0" e2="DrugDDI.d213.s9.e5" interaction="false"/><pair id="DrugDDI.d213.s9.p5" e1="DrugDDI.d213.s9.e1" e2="DrugDDI.d213.s9.e2" interaction="false"/><pair id="DrugDDI.d213.s9.p6" e1="DrugDDI.d213.s9.e1" e2="DrugDDI.d213.s9.e3" interaction="false"/><pair id="DrugDDI.d213.s9.p7" e1="DrugDDI.d213.s9.e1" e2="DrugDDI.d213.s9.e4" interaction="false"/><pair id="DrugDDI.d213.s9.p8" e1="DrugDDI.d213.s9.e1" e2="DrugDDI.d213.s9.e5" interaction="false"/><pair id="DrugDDI.d213.s9.p9" e1="DrugDDI.d213.s9.e2" e2="DrugDDI.d213.s9.e3" interaction="false"/><pair id="DrugDDI.d213.s9.p10" e1="DrugDDI.d213.s9.e2" e2="DrugDDI.d213.s9.e4" interaction="false"/><pair id="DrugDDI.d213.s9.p11" e1="DrugDDI.d213.s9.e2" e2="DrugDDI.d213.s9.e5" interaction="false"/><pair id="DrugDDI.d213.s9.p12" e1="DrugDDI.d213.s9.e3" e2="DrugDDI.d213.s9.e4" interaction="false"/><pair id="DrugDDI.d213.s9.p13" e1="DrugDDI.d213.s9.e3" e2="DrugDDI.d213.s9.e5" interaction="false"/><pair id="DrugDDI.d213.s9.p14" e1="DrugDDI.d213.s9.e4" e2="DrugDDI.d213.s9.e5" interaction="false"/></sentence><sentence id="DrugDDI.d213.s10" origId="s10" text="."/><sentence id="DrugDDI.d213.s11" origId="s11" text="- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard."><entity id="DrugDDI.d213.s11.e0" origId="s11.p120" charOffset="2-31" type="drug" text="Perhexiline hydrogen maleate"/><entity id="DrugDDI.d213.s11.e1" origId="s11.p122" charOffset="34-49" type="drug" text="MAO-inhibitors"/><entity id="DrugDDI.d213.s11.e2" origId="s11.p130" charOffset="117-124" type="drug" text="Bezalip"/><entity id="DrugDDI.d213.s11.e3" origId="s11.p132" charOffset="128-135" type="drug" text="Bezalip"/><pair id="DrugDDI.d213.s11.p0" e1="DrugDDI.d213.s11.e0" e2="DrugDDI.d213.s11.e1" interaction="false"/><pair id="DrugDDI.d213.s11.p1" e1="DrugDDI.d213.s11.e0" e2="DrugDDI.d213.s11.e2" interaction="true"/><pair id="DrugDDI.d213.s11.p2" e1="DrugDDI.d213.s11.e0" e2="DrugDDI.d213.s11.e3" interaction="true"/><pair id="DrugDDI.d213.s11.p3" e1="DrugDDI.d213.s11.e1" e2="DrugDDI.d213.s11.e2" interaction="true"/><pair id="DrugDDI.d213.s11.p4" e1="DrugDDI.d213.s11.e1" e2="DrugDDI.d213.s11.e3" interaction="true"/><pair id="DrugDDI.d213.s11.p5" e1="DrugDDI.d213.s11.e2" e2="DrugDDI.d213.s11.e3" interaction="false"/></sentence></document>